Gene · 974
Papers4,161
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 4,161
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Unveiling Primary Cutaneous B-Cell Lymphomas: New Insights into Diagnosis and Treatment Strategies. | Cancers (Basel) | 2025 | 40227781 | PubTator, text mining | PubMed |
| Broadening the Therapeutic Window of ADCs Using Site-Specific Bioconjugation Showcased by an MMAE-Containing Peptide Linker in a CD79b-Targeting ADC. | Mol Cancer Ther | 2025 | 40177869 | PubTator, text mining | PubMed |
| Building a new score system for the diagnosis and differential diagnosis of typical CLL/SLL, atypical CLL/SLL, and MCL based on the flow cytometry immunophenotyping. | Ann Hematol | 2025 | 40167603 | PubTator, text mining | PubMed |
| [Relapse-related candidate genes and their clinicopathological connections of diffuse large B cell lymphoma]. | Zhonghua Bing Li Xue Za Zhi | 2025 | 40159024 | PubTator, text mining | PubMed |
| Central Nervous System Manifestations of Cutaneous Lymphomas. | Curr Neurol Neurosci Rep | 2025 | 40131611 | PubTator, text mining | PubMed |
| Advances in primary large B-cell lymphoma of immune-privileged sites. | Front Immunol | 2025 | 40078990 | PubTator, text mining | PubMed |
| Comprehensive Analysis of Single-Cell and Bulk Transcriptomics Identified Regulatory T-Cell Features as Predictors of Prognosis in Diffuse Large B-Cell Lymphoma. | Hematol Oncol | 2025 | 40041930 | PubTator, text mining | PubMed |
| SOHO State of the Art Updates and Next Questions | Novel Immunotherapy Combinations for the Treatment of Indolent B-Cell Lymphoma. | Clin Lymphoma Myeloma Leuk | 2025 | 40011100 | PubTator, text mining | PubMed |
| Dynamics and activation of membrane-bound B cell receptor assembly. | Commun Biol | 2025 | 39948415 | PubTator, text mining | PubMed |
| High-Dose Methotrexate, Ibrutinib, and Temozolomide in the Treatment of Newly Diagnosed Primary CNS Lymphoma: A Multicenter, Prospective Phase II Study. | Blood Cancer Discov | 2025 | 39913173 | PubTator, text mining | PubMed |
| Epstein-Barr virus BALF0/1 subverts the Caveolin and ERAD pathways to target B cell receptor complexes for degradation. | Proc Natl Acad Sci U S A | 2025 | 39847318 | PubTator, text mining | PubMed |
| Mutational Profiling of Korean Lymphomas and Diffuse Large B-Cell Lymphoma Subtype Classification Using Targeted Panel Sequencing. | Arch Med Res | 2025 | 39765016 | PubTator, text mining | PubMed |
| Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic Leukemia. | Hematol Oncol | 2025 | 39716442 | PubTator, text mining | PubMed |
| TP53 Mutation Is the Only Robust Mutational Biomarker for Outcome Found in a Consecutive Clinical Cohort of Real-Word Patients With Primary Large B-Cell Lymphoma. | Eur J Haematol | 2025 | 39691999 | PubTator, text mining | PubMed |
| Primary large B-cell lymphoma of the central nervous system: A reappraisal of CD5-positive cases based on clinical, pathological, and molecular evaluation. | Pathol Int | 2025 | 39660959 | PubTator, text mining | PubMed |
| Distinct epigenetic and transcriptional profiles of Epstein-Barr virus-positive and negative primary CNS lymphomas. | Neuro Oncol | 2025 | 39575767 | PubTator, text mining | PubMed |
| High-grade B-cell lymphoma not otherwise specified, with diffuse large B-cell lymphoma gene expression signatures: Genomic analysis and potential therapeutics. | Am J Hematol | 2025 | 39548807 | PubTator, text mining | PubMed |
| High Prevalence of MYD88 and CD79B Mutations in Primary Sinonasal Diffuse Large B-Cell Lymphoma : Identification of an MCD-like Subtype. | Am J Surg Pathol | 2025 | 39483112 | PubTator, text mining | PubMed |
| Spheroid culture to select theoretical therapeutic drugs in intravascular large B-cell lymphoma. | Cancer Sci | 2025 | 39428323 | PubTator, text mining | PubMed |
| Targeted drug conjugates in cancer therapy: Challenges and opportunities. | Pharm Sci Adv | 2024 | 41550162 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/974/papers?page=11